Greco C, Pares O, Pimentel N, et al. - In this study, toxic effect profiles, prostate-specific antigen (PSA) responses, and quality-of-life endpoints of single-dose radiotherapy (SDRT) vs extreme hypofractionated stereotactic body radiotherapy (SBRT) were compared. Individuals were assigned randomly in a 1:1 ratio to receive 5 × 9 Gy SBRT (control arm) or 24 Gy SDRT (test arm). Researchers randomized a total of 30 men; median (interquartile range) age was 66.3 (61.2-69.9) and 73.6 (64.7-75.9) years for the SBRT and SDRT arms, respectively. The primary outcomes included toxic effects. PSA response, PSA relapse-free survival, and patient-reported quality of life measured with the International Prostate Symptom Score and Expanded Prostate Cancer Index Composite–26 questionnaires were considered as secondary outcomes. It was shown that SDRT was found to be safe and correlated with low toxicity, and the tumor control and quality-of-life endpoints closely match the SBRT arm outcomes in this randomized clinical trial among patients with intermediate-risk prostate cancer. There is a need for further trials to evaluate indications for SDRT in the cure of prostate cancer.